| abstract |
The present disclosure provides methods of using GSK3α-selective inhibitors for treating Fragile X syndrome, attention deficit hyperactivity disorder (ADHD), childhood seizure, intellectual disability, diabetes, acute myeloid leukemia (AML), autism, and psychiatric disorder. The GSK3α-selective inhibitors include compounds of Formula I-A. The present disclosure also provides methods of using GSK3β-selective inhibitors for treating a mood disorder, post-traumatic stress disorder (PTSD), psychiatric disorder, diabetes, and neurodegenerative disorder. The GSK3β-selective inhibitors include compounds of Formula I-B. |